ANRS 12300 Reflate TB2: RAL + 3TC/TDF Does Not Achieve Noninferior Efficacy vs EFV + 3TC/TDF at Wk 48 in ART-Naive Adults With HIV and TB

July 21-24, 2019; Mexico City, Mexico
First-line raltegravir 400 mg BID achieved HIV-1 RNA < 50 copies/mL in 61% of patients vs 66% with efavirenz 600 mg QD, each combined with 3TC/TDF in HIV/TB-coinfected patients receiving rifampin.
Format: Microsoft PowerPoint (.ppt)
File Size: 265 KB
Released: July 23, 2019


Provided by USF

USF Health
Office of Continuing Professional Development (OCPD)
124 S. Franklin Street
Tampa, FL 33602

(800) 852-5362
(813) 224-7860
(813) 224-7864 (Fax)

Produced in collaboration with
IAS 2019 Media Partner Logo
Educational grant provided by:
Gilead Sciences
ViiV Healthcare

Related Content

Clinical Care Options (CCO) presenta las reflexiones de la Dra. Leticia M. Pérez Saleme sobre cómo ha cambiado la atención de pacientes con VIH durante la pandemia de COVID-19 en México.

Leticia M. Pérez Saleme, MD Released: December 31, 2020

Multimedia module from Clinical Care Options: HIV experts review new/emerging strategies for initial HIV treatment, switching ART, and HIV prevention

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Daniel R. Kuritzkes, MD Paul E. Sax, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: December 30, 2020 Expired: December 29, 2021

Download free expert-authored slides reviewing current issues related to HIV care including weight gain, ART simplification, and ART safety in pregnancy

José R. Arribas, MD Released: December 23, 2020

CCO presents the reflections of Dra Leticia M. Pérez Saleme on how caring for her patients with HIV has changed during the COVID-19 epidemic in México.

Leticia M. Pérez Saleme, MD Released: December 23, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.